Pre-existing immunity modulates responses to mRNA boosters
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
mRNA vaccines are effective in preventing severe COVID-19, but breakthrough infections, emerging variants, and waning immunity warrant the use of boosters. Although mRNA boosters are being implemented, the extent to which pre-existing immunity influences the efficacy of boosters remains unclear. In a cohort of individuals primed with the mRNA-1273 or BNT162b2 vaccines, we report that lower antibody levels before boost are associated with higher fold-increase in antibody levels after boost, suggesting that pre-existing antibody modulates the immunogenicity of mRNA vaccines. Our studies in mice show that pre-existing antibodies accelerate the clearance of vaccine antigen via Fc-dependent mechanisms, limiting the amount of antigen available to prime B cell responses after mRNA boosters. These data demonstrate a "tug of war" between pre-existing antibody responses and de novo B cell responses following mRNA vaccination, and they suggest that transient downmodulation of antibody effector function may improve the efficacy of mRNA boosters.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Cell reports - 42(2023), 3 vom: 28. März, Seite 112167 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dangi, Tanushree [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.04.2023 Date Revised 13.05.2023 published: Print-Electronic UpdateOf: bioRxiv. 2022 Jun 28;:. - PMID 35794898 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2023.112167 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353631795 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353631795 | ||
| 003 | DE-627 | ||
| 005 | 20231226210035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2023.112167 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353631795 | ||
| 035 | |a (NLM)36857186 | ||
| 035 | |a (PII)S2211-1247(23)00178-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dangi, Tanushree |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pre-existing immunity modulates responses to mRNA boosters |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2023 | ||
| 500 | |a Date Revised 13.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2022 Jun 28;:. - PMID 35794898 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a mRNA vaccines are effective in preventing severe COVID-19, but breakthrough infections, emerging variants, and waning immunity warrant the use of boosters. Although mRNA boosters are being implemented, the extent to which pre-existing immunity influences the efficacy of boosters remains unclear. In a cohort of individuals primed with the mRNA-1273 or BNT162b2 vaccines, we report that lower antibody levels before boost are associated with higher fold-increase in antibody levels after boost, suggesting that pre-existing antibody modulates the immunogenicity of mRNA vaccines. Our studies in mice show that pre-existing antibodies accelerate the clearance of vaccine antigen via Fc-dependent mechanisms, limiting the amount of antigen available to prime B cell responses after mRNA boosters. These data demonstrate a "tug of war" between pre-existing antibody responses and de novo B cell responses following mRNA vaccination, and they suggest that transient downmodulation of antibody effector function may improve the efficacy of mRNA boosters | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a CP: Immunology | |
| 650 | 4 | |a Omicron variant | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody effector functions | |
| 650 | 4 | |a mRNA vaccines | |
| 650 | 4 | |a pre-existing immunity | |
| 650 | 4 | |a updated vaccines | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Sanchez, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Lew, Min Han |e verfasserin |4 aut | |
| 700 | 1 | |a Awakoaiye, Bakare |e verfasserin |4 aut | |
| 700 | 1 | |a Visvabharathy, Lavanya |e verfasserin |4 aut | |
| 700 | 1 | |a Richner, Justin M |e verfasserin |4 aut | |
| 700 | 1 | |a Koralnik, Igor J |e verfasserin |4 aut | |
| 700 | 1 | |a Penaloza-MacMaster, Pablo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 42(2023), 3 vom: 28. März, Seite 112167 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:3 |g day:28 |g month:03 |g pages:112167 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2023.112167 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 3 |b 28 |c 03 |h 112167 | ||